SEZ6L2

Across TCGA pan-cancer cohorts, SEZ6L2 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of SEZ6L2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where SEZ6L2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types SEZ6L2 is over-expressed in tumor, although a few such as OV show the opposite, repressed pattern.

CCRCC, HNSC, and LSCC are the cancer types where SEZ6L2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SEZ6L2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	III,IV	+0.634	<.001	11	view →
HNSC	All	IV	+1.086	<.001	8	view →
LSCC	All	III,IV	+0.451	.004	7	view →
LUAD	All	II,III,IV	+0.430	<.001	7	view →
OV	All	All	−0.490	.035	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

SEZ6L2–CCRCC

Open the CCRCC breakdown →